54 studies found for:    Elvitegravir OR Elvitegravir[TREATMENT] AND HIV [CONDITION]
Show Display Options
Rank Status Study
21 Not yet recruiting Strategy for Maintenance of HIV Suppression With Elvitegravir + Darunavir/Ritonavir in Children
Condition: HIV Infection
Interventions: Drug: EVG +DRV/r;   Drug: SOC
22 Completed
Has Results
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: PI;   Drug: RTV;   Drug: FTC/TDF;   Drug: Stribild
23 Recruiting An Open Label Trial of Stribild for Antiretroviral (ARV)-naïve HIV-2 Infected Adults in Dakar, Senegal
Condition: HIV-2 Infection
Intervention: Drug: Stribild (Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF) 1 tablet daily X 48 weeks
24 Recruiting Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I
Condition: HIV-1 Infection
Intervention: Drug: E/C/F/TAF
25 Not yet recruiting HIV Drug Switch Followed by HCV Therapy in HIV-HCV Co-Infection
Conditions: Human Immunodeficiency Virus;   Hepatitis C, Chronic
Interventions: Drug: E/C/F/TAF;;   Drug: Ledipasvir-Sofosbuvir
26 Recruiting Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study
Conditions: Hepatitis C Infection;   HIV Infection
Intervention: Drug: Sofosbuvir, Ribavirin, and Stribild
27 Completed Relative Bioavailability and Food Effect for Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination
Condition: Healthy
Interventions: Drug: Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide FDC;   Drug: Elvitegravir /Cobicistat/Emtricitabine/Tenofovir alafenamide FDC;   Drug: Darunavir;   Drug: Emtricitabine/Tenofovir alafenamide (FTC/TAF);   Drug: Cobicistat;   Other: High-fat Breakfast;   Other: Standardized Regular Breakfast
28 Active, not recruiting Atripla to Stribild Switch Study to Evaluate Sleep Disturbances
Conditions: HIV;   AIDS;   Sleep Disorders
Intervention: Drug: elvitegravir/ cobicistat/ emtricitabine/ tenofovir disoproxil
29 Active, not recruiting Treatment of Acute HIV Infection With Quad Fixed-dose Combination (FDC) Tablet
Condition: HIV
Intervention: Drug: (FDC) ELV/COBI/FTC/TDF
30 Active, not recruiting Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Adolescents
Condition: HIV
Intervention: Drug: E/C/F/TAF
31 Not yet recruiting Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive
Conditions: Patient Compliance;   Antiretroviral Therapy Intolerance
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir;   Drug: Darunavir;   Drug: abacavir/lamivudine;   Drug: Ritonavir;   Drug: Lamivudine;   Drug: rilpivirine
32 Recruiting Sleep and Cognition After Atripla to Stribild Switch
Condition: HIV
Interventions: Drug: Stribild;   Drug: Atripla
33 Completed
Has Results
Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
Conditions: HIV;   HIV Infections
Interventions: Drug: Stribild;   Drug: Atripla;   Drug: Stribild Placebo;   Drug: Atripla Placebo
34 Active, not recruiting
Has Results
Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: E/C/F/TDF;   Drug: E/C/F/TAF Placebo;   Drug: E/C/F/TAF;   Drug: E/C/F/TDF Placebo
35 Completed
Has Results
Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
Conditions: HIV;   HIV Infections
Interventions: Drug: Stribild;   Drug: ATV;   Drug: Ritonavir;   Drug: FTC/TDF;   Drug: Stribild Placebo;   Drug: ATV Placebo;   Drug: RTV Placebo;   Drug: FTC/TDF Placebo
36 Recruiting HIV Non-Occupational Post-Exposure Prophylaxis
Condition: Human Immunodeficiency Virus
Intervention: Drug: Coformulated Elivitegravir (150mg), Combicistat (150mg), Emtricitabine (200mg), Tenofovir DF (300mg)
37 Completed
Has Results
Study of the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
Conditions: HIV;   HIV Infections
Interventions: Drug: Stribild;   Drug: Atripla
38 Active, not recruiting
Has Results
Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults
Conditions: HIV;   HIV Infections
Interventions: Drug: E/C/F/TAF;   Drug: E/C/F/TDF;   Drug: E/C/F/TDF Placebo;   Drug: E/C/F/TAF Placebo
39 Active, not recruiting
Has Results
Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults
Conditions: HIV;   HIV Infections
Interventions: Drug: E/C/F/TAF;   Drug: E/C/F/TDF;   Drug: E/C/F/TDF Placebo;   Drug: E/C/F/TAF Placebo
40 Recruiting Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults
Condition: HIV-1 Infection
Interventions: Drug: E/C/F/TAF;   Drug: ABC/3TC;   Drug: Third Antiretroviral Agent

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-54) Show next page of results    Last Page
Indicates status has not been verified in more than two years